NY-AIRCALL
Aircall, the business phone system, today announced that Michael Haske will join the company as Chief Executive Officer (CEO) effective September 2, 2022. Haske, previously the President and Chief Operating Officer at Paylocity, will succeed Aircall CEO Olivier Pailhes. Pailhes co-founded Aircall in 2014 and has led the global company to achieve over $1bn valuation and scale to serve more than 13,000 customers in over 100 countries. Pailhes will remain on the board and continue to serve as a strategic advisor to the company.
Haske joins Aircall at a pivotal time as the company has recently reached centaur status with $100m Annual Recurring Revenue (ARR) and continues to expand globally. He brings nearly three decades of experience in scaling high-growth, cloud-based software businesses and will continue driving Aircall’s global leadership in the cloud communications industry and further its mission to empower every professional to have richer conversations.
“ Michael not only brings the right experience and leadership to accelerate Aircall’s global momentum, he deeply understands the importance of cultivating a diverse, employee-centric culture – which has been instrumental to Aircall’s success to date. I am very proud of the hard work and success the Aircall team has delivered so far, and this change is a testimony of our ambition to build a global leader in the communications space.” — Olivier Pailhes, CEO and Co-Founder, Aircall
Haske most recently served as President and Chief Operating Officer of cloud-based Payroll & Human Resources software company Paylocity, where he led the company’s growth from 100 employees and $15 million in revenue to being on track to reach 5,000 employees and $1 billion in revenue. In 2014 Haske and the Paylocity leadership team took the company public on NASDAQ under ticker symbol PCTY. He’s also served in multiple leadership roles including Executive Sponsor at Blue Marble Payroll, Director of Marketing for Paychex (NASDAQ : PAYX) and various roles with ADP (NYSE : ADP).
“ Olivier and Jonathan set a strong foundation and built an incredible company and culture with tremendous potential and opportunity ahead. It’s an exciting time to be joining Aircall and I look forward to leading its next evolution as we continue to provide the most modern cloud communications tools to our clients and strive to be one the best places to work in the world for our employees. It's an honor to lead the company into its next chapter and beyond.” — Michael Haske, Incoming CEO, Aircall
Pailhes, alongside his co-founders Jonathan Anguelov, Pierre-Baptiste Béchu and Xavier Durand, launched Aircall in 2014 after seeing the need for a better communication platform for businesses to interact with their customers. Jonathan Anguelov will remain in his role as General Manager of Aircall’s EMEA and APAC business. Worldwide, Aircall is among a small group of 150 private SaaS companies to reach Centaur status and will continue building on this recent achievement with expansion plans in Singapore and Madrid later this year.
About Aircall
Aircall is the phone system for modern businesses. An entirely cloud-based voice platform that integrates with popular productivity and help desk tools such as Salesforce, Hubspot, Slack, and many others, Aircall was built to make phone support easy to manage, accessible, transparent, and collaborative. Aircall believes that voice is the most powerful way to communicate with customers, prospects, candidates, and colleagues. It is designed to enable delightful moments of human connection. Aircall was founded in 2014 and has raised over $226 million in funding. With offices in New York, Paris, Sydney, Berlin, London, and Madrid, the company currently has over 700+ employees.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005779/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom